25682 Federal Register / Vol. 61, No. 100 / Wednesday, May 22, 1996 / Notices

FISCAL YEAR 1996 FEDERAL ALLOTMENTS TO STATES FOR SOCIAL SERVICES—TITLE XX BLOCK GRANTS—Continued

Initial FY 96 allotment Revised FY 96 allotment

MICHIGAN ................................................................................................................... 102,323,614 87,011,617

MINNESOTA ................................................................................................................ 48,765,115 41,467,764

MISSISSIPPI ................................................................................................................ 28,533,584 24,263,738

MISSOURI .................................................................................................................... 56,505,781 48,050,095

MONTANA ................................................................................................................... 9,068,563 7,711,516

NEBRASKA .................................................................................................................. 17,349,024 14,752,866

NEVADA ....................................................................................................................... 14,995,516 12,751,544

NEW HAMPSHIRE ...................................................................................................... 12,156,192 10,337,105

NEW JERSEY .............................................................................................................. 85,060,957 72,332,192

NEW MEXICO .............................................................................................................. 17,446,187 14,835,490

NEW YORK .................................................................................................................. 196,453,134 167,055,326

NORTH CAROLINA ..................................................................................................... 74,977,580 63,757,721

NORTH DAKOTA ......................................................................................................... 6,866,197 5,838,721

NO. MARIANA ISLANDS ............................................................................................. 96,552 82,103

OHIO ............................................................................................................................ 119,737,413 101,819,564

OKLAHOMA ................................................................................................................. 34,881,578 29,661,800

OREGON ..................................................................................................................... 32,733,192 27,834,905

PENNSYLVANIA .......................................................................................................... 129,982,730 110,531,742

PUERTO RICO ............................................................................................................ 14,482,759 12,315,515

RHODE ISLAND .......................................................................................................... 10,806,704 9,189,557

SOUTH CAROLINA ..................................................................................................... 39,329,492 33,444,114

SOUTH DAKOTA ......................................................................................................... 7,729,870 6,573,150

TENNESSEE ................................................................................................................ 55,048,334 46,810,744

TEXAS .......................................................................................................................... 194,661,013 165,531,384

UTAH ............................................................................................................................ 20,080,388 17,075,502

VERMONT ................................................................................................................... 6,229,239 5,297,077

VIRGIN ISLANDS ........................................................................................................ 482,759 410,515

VIRGINIA ...................................................................................................................... 70,076,237 59,589,828

WASHINGTON ............................................................................................................. 56,732,495 48,242,884

WEST VIRGINIA .......................................................................................................... 19,648,552 16,708,287

WISCONSIN ................................................................................................................. 54,389,783 46,250,742

WYOMING ................................................................................................................... 5,084,873 4,323,960

DATED: May 10, 1996.

Donald Sykes,

Director Office of Community Services.

[FR Doc. 96–12860 Filed 5–21–96; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Peripheral and Central Nervous

System Drugs Advisory Committee

Date, time, and place. June 6, 1996,

8:30 a.m., Holiday Inn—Bethesda,

Versailles Ballrooms III and IV, 8120

Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person.

Open public hearing, 8:30 a.m. to 9 a.m.,

unless public participation does not last

that long; open committee discussion, 9

a.m. to 3 p.m.; open public hearing, 3

p.m. to 3:30 p.m., unless public

participation does not last that long;

William Freas or Sheila D. Langford,

Center for Biologics Evaluation and

Research (HFM–21), Food and Drug

Administration, 1401 Rockville Pike,

Bethesda, MD 20852, 301–827–0314, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Peripheral and Central Nervous System

Drugs Advisory Committee, code 12543.

Please call the hotline for information

concerning any possible changes.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational human

drugs for use in neurological disease.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before May 31, 1996, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. The

committee will discuss product license

application 96–0350 for ActivaseTM

(alteplase), Genentech, for the

management of acute ischemic stroke.
Federal Register / Vol. 61, No. 100 / Wednesday, May 22, 1996 / Notices 25683

Antiviral Drugs Advisory Committee

Date, time, and place. June 6 and 7,

1996, 8:30 a.m., Quality Hotel,

Maryland Ballroom, 8727 Colesville Rd.,

Silver Spring, MD.

Type of meeting and contact person.

Open committee discussion, June 6,

1996, 8:30 a.m. to 11 a.m.; open public

hearing, 11 a.m. to 12 m., unless public

participation does not last that long;

open committee discussion, 12 m. to 5

p.m.; open committee discussion, June

7, 1996, 8:30 a.m. to 11 a.m.; open

public hearing, 11 a.m. to 12 m., unless

public participation does not last that

long; open committee discussion, 12 m.

to 5 p.m.; Rhonda W. Stover or Liz

Ortuzar, Center for Drug Evaluation and

Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–4695, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Antiviral Drugs Advisory Committee,

code 12531. Please call the hotline for

information concerning any possible

changes.

General function of the committee.

The committee reviews and evaluates

available data concerning the safety and

effectiveness of marketed and

investigational human drug products for

use in the treatment of acquired

immune deficiency syndrome (AIDS),

AIDS-related complex (ARC), and other

viral, fungal, and mycobacterial

infections.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before May 31, 1996, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. On June

6, 1996, the committee will discuss data

relevant to new drug application (NDA)

20–585, Bravavir (sorivudine), Bristol

Myers Squibb, for use in the treatment

of herpes zoster in

immunocompromised adults. On June 7,

1996, the committee will discuss data

relevant to NDA 20–636, Viramune

(nevirapine), Boehringer Ingelheim, for

use in the treatment of human

immunodeficiency virus infection.

Peripheral and Central Nervous

System Drugs Advisory Committee

Date, time, and place. June 7, 1996,

8:30 a.m., Holiday Inn—Bethesda,

Versailles Ballrooms III and IV, 8120

Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person.

Open committee discussion, 8:30 a.m. to

4 p.m.; open public hearing, 4 p.m. to

5 p.m., unless public participation does

not last that long; Michael A. Bernstein,

Center for Drug Evaluation and Research

(HFD–120), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–594–2775, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Peripheral and Central Nervous System

Drugs Advisory Committee, code 12543.

Please call the hotline for information

concerning any possible changes.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational human

drugs for use in neurological disease.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before June 1, 1996, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. The

committee will review data from two

clinical studies which evaluated

Myotrophin’s utility in treating

patients with amyotrophic lateral

sclerosis. Data from these studies have

been submitted to FDA in support of a

treatment protocol, investigational new

drug application 39,927, Cephalon, Inc.

Advisory Committee for Reproductive

Health Drugs (formerly Fertility and

Maternal Health Drugs Advisory

Committee)

Date, time, and place. June 28, 1996,

9 a.m., Holiday Inn—Gaithersburg,

Whetstone and Walker Rooms, Two

Montgomery Village Ave., Gaithersburg,

MD.

Type of meeting and contact person.

Open committee discussion, 9 a.m. to 5

p.m.; open public hearing, at the

completion of the formal presentations,

at approximately 2 p.m. to 3 p.m.,

unless public participation does not last

that long; Philip A. Corfman, Center for

Drug Evaluation and Research (HFD–

510), Food and Drug Administration,

5600 Fishers Lane, Rockville, MD

20857, 301–443–3510, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Advisory

Committee for Reproductive Health

Drugs, code 12537. Please call the

hotline for information concerning any

possible changes.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational human

drugs for use in the practice of obstetrics

and gynecology.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before June 17, 1996, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. The

committee will discuss the safety and

efficacy of certain oral contraceptives

for postcoital emergency use. Over the

years, there has been increasing interest

in this use by health care professionals

and consumers. This use has been

approved in some countries, and

physicians have prescribed oral

contraceptives for emergency use in the

United States, although contraceptives

marketed in the United States are not

labeled for this use. On November 23,

1994, the Center for Reproductive Law

and Policy submitted a citizen’s petition

requesting FDA to direct sponsors of

certain oral contraceptives to amend the

labeling and patient package inserts to

include information regarding the use of

these products for postcoital emergency

contraception (Docket No. 94P–0427).

FDA denied the petition but determined

that it would be appropriate to discuss

the scientific issues related to the safety

and effectiveness of this use with the

Reproductive Health Drugs Advisory

Committee to determine whether the

data support the use under certain

conditions.

FDA public advisory committee

meetings may have as many as four

separable portions: (1) An open public

hearing, (2) an open committee

discussion, (3) a closed presentation of

data, and (4) a closed committee

deliberation. Every advisory committee

meeting shall have an open public

hearing portion. Whether or not it also

includes any of the other three portions

will depend upon the specific meeting

involved. There are no closed portions

for the meetings announced in this

notice. The dates and times reserved for

the open portions of each committee

meeting are listed above.
25684 Federal Register / Vol. 61, No. 100 / Wednesday, May 22, 1996 / Notices

The open public hearing portion of

each meeting shall be at least 1 hour

long unless public participation does

not last that long. It is emphasized,

however, that the 1 hour time limit for

an open public hearing represents a

minimum rather than a maximum time

for public participation, and an open

public hearing may last for whatever

longer period the committee

chairperson determines will facilitate

the committee’s work.

Public hearings are subject to FDA’s

guideline (subpart C of 21 CFR part 10)

concerning the policy and procedures

for electronic media coverage of FDA’s

public administrative proceedings,

including hearings before public

advisory committees under 21 CFR part

14. Under 21 CFR 10.205,

representatives of the electronic media

may be permitted, subject to certain

limitations, to videotape, film, or

otherwise record FDA’s public

administrative proceedings, including

presentations by participants.

Meetings of advisory committees shall

be conducted, insofar as is practical, in

accordance with the agenda published

in this Federal Register notice. Changes

in the agenda will be announced at the

beginning of the open portion of a

meeting.

Any interested person who wishes to

be assured of the right to make an oral

presentation at the open public hearing

portion of a meeting shall inform the

contact person listed above, either orally

or in writing, prior to the meeting. Any

person attending the hearing who does

not in advance of the meeting request an

opportunity to speak will be allowed to

make an oral presentation at the

hearing’s conclusion, if time permits, at

the chairperson’s discretion.

The agenda, the questions to be

addressed by the committee, and a

current list of committee members will

be available at the meeting location on

the day of the meeting.

Transcripts of the open portion of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, rm. 12A–16, 5600

Fishers Lane, Rockville, MD 20857,

approximately 15 working days after the

meeting, at a cost of 10 cents per page.

The transcript may be viewed at the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, approximately 15

working days after the meeting, between

the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of

the open portion of the meeting may be

requested in writing from the Freedom

of Information Office (address above)

beginning approximately 90 days after

the meeting.

This notice is issued under section

10(a)(1) and (2) of the Federal Advisory

Committee Act (5 U.S.C. app. 2), and

FDA’s regulations (21 CFR part 14) on

advisory committees.

Dated: May 16, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–12797 Filed 5–21–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4042–N–02]

Office of the Assistant Secretary for

Community Planning and

Development; Notice of Funding

Availability for Continuum of Care

Homeless Assistance; Clarification;

Supportive Housing Program (SHP);

Shelter Plus Care (S+C); Section 8

Moderate Rehabilitation Single Room

Occupancy Program for Homeless

Individuals (SRO)

AGENCY: Office of the Assistant

Secretary for Community Planning and

Development, HUD.

ACTION: Notice of funding availability

(NOFA); clarification.

SUMMARY: On March 15, 1996 (61 FR

10866), HUD published a notice

announcing the availability of fiscal

year (FY) 1996 funding for three of its

programs which assist communities in

combatting homelessness. The three

programs are: (1) Supportive Housing;

(2) Shelter Plus Care; and (3) Section 8

Moderate Rehabilitation for Single

Room Occupancy Dwellings for

Homeless Individuals. The Congress

had not yet enacted a FY 1996

appropriation for HUD at the time of

publication of the March 15, 1996 notice

of funding availability (NOFA).

Accordingly, the March 15, 1996 NOFA

set forth HUD’s estimate of the FY 1996

funding that the Congress would make

available. The Congress has since

enacted a FY 1996 appropriation for

HUD. This notice provides the final FY

1996 amount made available under the

March 15, 1996 NOFA.

DEADLINE DATES: The original

application deadline date is not

changed. All applications are due in

HUD Headquarters before midnight

Eastern Time on June 12, 1996. HUD

will treat as ineligible for consideration

applications that are received after that

deadline. Applications may not be sent

by facsimile (FAX).

ADDRESSES: For a copy of the

application package and supplemental

information please call the Community

Connections information center at 1–

800–998–9999 (voice) or 1–800–483–

2209 (TDD), or contact by internet at

gopher://amcom.aspensys.com:75/11/

funding. Also, you can purchase, for a

nominal fee, a video that walks you

through the application package and

provides general background that can be

useful in preparing your application.

The fee for the video may be waived in

cases of financial hardship. For copies

of the relevant portions of your

community’s Consolidated Plan, please

contact the local or State official

responsible for that Plan. If you need

assistance in identifying this person,

please call your local HUD Field Office.

Before close of business on the

deadline date completed applications

will be accepted at the following

address: Special Needs Assistance

Programs, Room 7270, Office of

Community Planning and Development,

Department of Housing and Urban

Development, 451 Seventh Street, S.W.,

Washington, DC 20410, Attention:

Continuum of Care Funding. On the

deadline date, hand-carried applications

will be received at the South lobby of

the Department of Housing and Urban

Development at the above address. Two

copies of the application must also be

sent to the HUD Field Office serving the

State in which the applicant’s projects

are located. A list of Field Offices

appears in an appendix of this NOFA.

Field Office copies must be received by

the application deadline as well, but a

determination that an application was

received on time will be made solely on

receipt of the application at HUD

Headquarters in Washington.

ELECTRONIC SUBMISSION: In addition to

submitting the application narratives

and forms in the traditional manner,

you may also include an electronic

version of your materials on a 31⁄2′

computer diskette. The inclusion of the

computer version this year is strictly an

optional supplement to the standard

application.

If you use HUD’s Consolidated

Planning software to generate

supplemental maps, charts, or project

lists, please include these files on the

diskette as well.

FOR FURTHER INFORMATION CONTACT: The

Community Connections information

center at 1–800–998–9999 (voice) or 1–

800–483–2209 (TDD), or by internet at

gopher://amcom.aspensys.com:75/11/

funding.